相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Signaling by the Phosphoinositide 3-Kinase Family in Immune Cells
Klaus Okkenhaug
ANNUAL REVIEW OF IMMUNOLOGY, VOL 31 (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia
Ines M. Macias-Perez et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2013)
Inhibitors of B-Cell Receptor Signaling for Patients With B-Cell Malignancies
Michael Y. Choi et al.
CANCER JOURNAL (2012)
Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network
A. Smith et al.
BRITISH JOURNAL OF CANCER (2011)
Receptor Tyrosine Kinases and TLR/IL1 Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression
Michael C. Schmid et al.
CANCER CELL (2011)
Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
Kirsten Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W. Friedberg et al.
BLOOD (2010)
Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies
Bruce D. Cheson
JOURNAL OF CLINICAL ONCOLOGY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
The emerging mechanisms of isoform-specific PI3K signalling
Bart Vanhaesebroeck et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2010)
Phosphoinositide signalling in cancer: beyond PI3K and PTEN
Tom D. Bunney et al.
NATURE REVIEWS CANCER (2010)
Bendamustine for the Treatment of Chronic Lymphocytic Leukemia and Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Trevor W. Dennie et al.
CLINICAL THERAPEUTICS (2009)
Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
Stephan Stilgenbauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia
Wolfgang U. Knauf et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
Constantine S. Tam et al.
BLOOD (2008)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Isoform-specific functions of phosphoinositide 3-kinases:: p110δ but not p110γ promotes optimal allergic responses in vivo
Khaled Ali et al.
JOURNAL OF IMMUNOLOGY (2008)
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
Bertrand Coiffier et al.
BLOOD (2008)
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
Peter Hillmen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
D. Catovsky et al.
LANCET (2007)
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997
Michael R. Grever et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Revised response criteria for malignant lymphoma
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Results of first salvage therapy for patients refractory to a fluidarabine regimen in chronic lymphocytic leukemia
MJ Keating et al.
LEUKEMIA & LYMPHOMA (2002)
分享论文
